CARCINOMA OF THE CERVIX

BIOLOGY AND DIAGNOSIS

edited by

E.S.E. HAFEZ and J.P. SMITH

School of Medicine, Wayne State University, Detroit, Michigan, U.S.A.

1982

MARTINUS NIJHOFF PUBLISHERS

THE HAGUE/BOSTON/LONDON
Distributors:

for the United States and Canada

Kluwer Boston, Inc.
190 Old Derby Street
Hingham, MA 02043
USA

For all other countries

Kluwer Academic Publishers Group
Distribution Center
P.O. Box 322
3300 AH Dordrecht
The Netherlands

Library of Congress Cataloging in Publication Data

Main entry under title:

Carcinoma of the cervix.

(Developments in obstetrics and gynecology, ISSN 90-247-2334-5 ; v. 6)
Includes index.
AC280.U8C374 616.99'4 81-22436
ISBN 90-247-2574-7 AARC2

ISBN 90-247-2334-5 (series)
# TABLE OF CONTENTS

## Preface

IX

## Contributors

XI

## Acknowledgements

XIV

## I. EPIDEMIOLOGY

1. U.S. trends in carcinoma of the cervix: incidence mortality and survival  
   G. Marie Swanson, S.H. Belle and J.L. Young, Jr.  
   1

   M.J. Brennan, Ann Grossbart and G. Marie Swanson  
   10

3. Invasive carcinoma of the uterine cervix in women younger than 25 years  
   C.J. Castellano, L. Conroy and G. Ramirez  
   15

4. Cervical carcinoma in Panama  
   R.C. de Britton, W.C. Reeves, P.F. Valdés, C.F.B. Joplin and M.M. Brenes  
   22

5. Cervical carcinoma detection and mortality in Chile  
   A. Dabancens  
   26

6. Cervical carcinoma in El Salvador  
   N. Díaz-Bazán  
   28

7. Cervical carcinoma in Kuwait  
   H. Hathout, S. Motawy and S. Hassan  
   33

8. Abnormal cervical cytology in Jamaica  
   J. St. E. Hall  
   36

## II. GROWTH PATTERNS, STRUCTURE AND ULTRASTRUCTURE

9. Growth patterns of microinvasive carcinoma of the cervix  
   J.C. Seski and W.A. Schmidt  
   45

10. Growth, spread and grading in squamous cell carcinoma of the uterine cervix  
    J. Baltzer, K.J. Lohe and J. Zander  
    57
11. Microinvasive carcinoma of the cervix: definition and behavior  
   G.R. SCHRODT and W.M. CHRISTOPHERSON .................................................. 62
12. Hyperkeratotic cervical dysplasia  
   R.A. KOMOROWSKI and E.J. WILKINSON ........................................................ 69
13. Mucoepidermoid carcinoma of the cervix  
   H.P. DINGES and J. ZEITLHOFER .................................................................. 74
14. Morphometric analysis of basal cell-stroma interface in normal and abnormal cervical epithelium  
   L.B. TWIGGS, T. OKAGAKI and BARBARA A. CLARK ..................................... 79
15. SEM of neoplasia of the cervical epithelium  
   J.A. JORDAN and J.M. ALLEN ..................................................................... 87
16. Surface ultrastructure of the uterine cervix and early detection of irreversible neoplasia  
   P. KENEMANS, J.H.M. DAVINA, R.W. DE HAAN, P.H.T. VAN DER ZANDEN, G.P. VOOYS and A.M. STADHOUDELS 91
17. Histochemistry of alkaline phosphatase in cervical neoplasia  
   S. NOZAWA, H. OOTA, K. ARAI, S. IZUMI, F. TSUTSUI and S. KURIHARA ...... 100
18. Morphology of the basement membrane in carcinoma of the cervix  
   U.M. SPORNITZ and E.S.E. HAFEZ .................................................................. 109

III. ETIOLOGY

19. Role of sperm basic proteins as carcinogens in cervical cancer  
   P.W. FRENCH, M. COPPLESON, B.L. REID and A. SINGER ............................ 123
20. Expression of herpes virus antigen in premalignant and malignant cervix  
   G.A. CABRAL, F. MARCIANO-CABRAL, D. FRY, H. TOMLIN, D. HALL and D. GOPLERUD 128
21. Immunological aspects of squamous cell carcinoma of the uterine cervix: use of leukocyte adherence inhibition assay  
   M.M. DINI and I. FAIFFERMAN .................................................................. 138
22. Human cell line (SKG-1) derived from epidermoid cancer of the cervix  
   S. NOZAWA, K. TSUKAZAKI, Y. UDAKAWA, I. ISHIWATA, H. OOTA, S. KURIHARA and H. OKUMURA 142
23. Effect of oral contraceptives and IUDs on cervical carcinogenesis  
   U. HERMANN and E.S.E. HAFEZ ................................................................. 152

IV. DIAGNOSIS AND PROGNOSIS

24. Diagnostic dilemma of recurrent cervical carcinoma  
   J.H. SHEPHERD, H. PRAPHT, E. RUFFOLO and D. CAVANAGH .......................... 173
25. Prognostic factors in carcinoma of the cervix  
   H.R.K. BARBER, S. SOMMERS and A. ROMOFF .............................................. 180
26. Colposcopy and cytology for the diagnosis of early cervical carcinoma 184
   U. Hermanns, H. Amirikia and E.S.E. Hafez

27. Outpatient diagnosis and selection of treatment of cervical intraepithelial neoplasia using 195
    colposcopy
   K.D. Hatch, H.M. Singleton and Hazel Gore

28. Adenocarcinoma of the cervix: histopathologic and clinical features 200
    H.M. Singleton, Hazel Gore and J.H. Wilters

29. Distinction between cervical and endometrial adenocarcinoma with immunoperoxidase staining 210
    of carcinoembryonic antigen
   M. Korhonen, T. Wahlstrom, J. Lindgren and M. Seppala

30. Lymphography, angiography and phlebography in the staging and follow-up of cervical 215
    carcinoma
   A. Onnis, L. Labi and S. Valente

31. Concluding remarks: future research 223
    E.S.E. Hafez

Subject index 253
CONTRIBUTORS

ALLEN, J.M.: Birmingham Maternity Hospital, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, B15 2TG United Kingdom.

AMIRKIA, H.: Department of Gynecology and Obstetrics, Wayne State University School of Medicine, Detroit, MI 48201, U.S.A.


BARBER, H.R.K.: Department of Obstetrics and Gynecology, Lenox Hill Hospital and New York Medical College, 100 East 77 Street, New York, NY 10021, U.S.A.

BELLE, S.H.: Medical Division, Department of Social Oncology, Michigan Cancer Foundation, Detroit, MI 48201, U.S.A.

BRENS, M.M.: Gorgas Memorial Laboratory, Apartado 6991, Panama 5, República de Panamá.

BRENNAN, M.J.: Medical Division, Department of Social Oncology, Michigan Cancer Foundation, 110 E. Warren Avenue, Detroit, MI 48201, U.S.A.


CABRAL, G.A.: Department of Microbiology, Medical College of Virginia/VCU, MCV Station, Richmond, VA 23298, U.S.A.

CASTELLANO, C.J.: Departments of Gynecology and Pathology, Instituto Nacional Enfermedades Neoplásicas, Av. Alfonso Ugarte 825, Lima 1, Peru.

CAVANAGH, D.: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida, 12901 North 30th Street, Tampa, FL 33612, U.S.A.

CHRIJSTHOFENSON, W.M.: Department of Pathology, University of Louisville, Health Sciences Center, Louisville, KY 40292, U.S.A.

CLARK, BARBARA A.: Department of Obstetrics and Gynecology, University of Minnesota Medical School, 420 Delaware Street S.E., Box 395 Mayo Memorial Building, Minneapolis, MN 55455, U.S.A.

CONROY, L.: Departments of Gynecology and Pathology, Instituto Nacional Enfermedades Neoplásicas, Av. Alfonso Ugarte 825, Lima 1, Peru.

COPELISSON, M.: King George V Memorial Hospital, Sydney, Australia.

DOBANESCH, A.: Service of Cytopathology and Control of Cancer, University of Chile, Casilla 6606, Correo 4 - Santiago, Chile.


DIAZ-BAZÁN, N.: Department of Surgery 'Hospital Rosas', National Medical Center, Oncology School of Medicine, University of El Salvador, San Salvador, El Salvador, C.A.


DINN, M.M.: Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, Cook County Hospital, 1835 W. Harrison Street, Chicago, IL 60612, U.S.A.

FAIFERMAN, I.: Department of Pathology, University of Illinois, Chicago, IL 60612, U.S.A.

FRENCH, P.W.: Queen Elizabeth II Research Institute, The University of Sydney, Sydney, 2006 Australia.

FRY, D.: Department of Microbiology, Medical College of Virginia/VCU, MCV Station, Richmond, VA 23298, U.S.A.

GOLPERUD, D.: Department of Obstetrics/Gynecology, Medical College of Virginia/VCU, MCV Station, Richmond, VA 23298, U.S.A.

GORE, HAZEL: Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, The University of Alabama in Birmingham, University Station, Birmingham, AL 35294, U.S.A.

GROSSBART, ANN: Medical Division, Department of Social Oncology, Michigan Cancer Foundation, 110 E. Warren Avenue, Detroit, MI 48201, U.S.A.

HAAN, R.W. DE: Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Catholic University of Nijmegen, Geert Grooteplein Zuid 14, 6500 HB Nijmegen, The Netherlands.

HAFF, E.S.E.: Department of Gynecology and Obstetrics, Wayne State University School of Medicine, Detroit, MI 48201, U.S.A.

HALL, D.: Department of Obstetrics/Gynecology, Medical College of Virginia/VCU, MCV Station, Richmond, VA 23298, U.S.A.

HALL, J. ST.: Department of Obstetrics and Gynecology, University of the West Indies, Mona, Kingston 7, Jamaica.

HASSAN, S.: Department of Pathology, Al-Sabah Hospital, P.O. Box 4078, Kuwait, Arabia.

HATCH, K.D.: Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, The University of Alabama in Birmingham, University Station, Birmingham, AL 35294, U.S.A.

HAITHOUT, H.: Department of Obstetrics and Gynecology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Kuwait, Arabia.

HAYASHI, S.: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan.

HEINRICH, U.: Städtische Frauenklinik, Osnabrück, West Germany.
YOUNG, J.L., JR.: Biometry Branch, National Cancer Institute, Landow Building, 7910 Woodmont Avenue, Bethesda, MD 20205, U.S.A.

ZANDEN, P.H.T., VAN DER: Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Catholic University of Nijmegen, Geert Grooteplein Zuid 14, 6500 HB Nijmegen, The Netherlands.

ZANDER, J.: I. Frauenklinik der Universität München, Mastrasse 11, D-8000 München 2, West Germany.

ZEITLHOFFER, J.: Department of Pathology, Kaiser-Franz-Josef-Spital, Kundratstrasse 3, A-1100 Vienna, Austria.
1. CANCER AS A HEALTH PROBLEM IN PANAMA

1. A. Mortality

Tropical countries have historically devoted most of their health resources to infectious diseases. In countries such as Panama with rapidly improving environmental and health standards, infectious diseases remain the principal cause of morbidity but not mortality. Along with the population’s increasing life span, non-infectious chronic diseases have emerged as major public health problems. Panama’s published cause-specific mortality rates show this (Table 1); cancer has been among the three principal causes of death since 1968 (Dirección de Estadística y Censo 1979). These crude death rates contradict the fact that more than half of Panama’s population is younger than 15 years. A similar mortality pattern appears to be evolving in other tropical countries.

1. B. Incidence

The National Oncology Institute of Panama initiated a National Cancer Register in 1974 to document cancer incidence (Valdés et al. 1979). The Panama National Cancer Register actively ascertains all histologically diagnosed cancers by annually reviewing every certified pathologist’s histology reports. Registration includes each cancer patient’s name, age, sex, hospital/clinic/chart numbers, date of diagnosis, anatomic site, and town where the tissue specimen was obtained (this allows a crude estimation of residence). Registry information is coded (cancer site according to the Ninth Revision of the International Classification of Diseases), and all data is maintained on interactive disc files on the Gorgas Memorial Laboratory computer. Duplicate registration is monitored by checking the patient’s name and hospital/clinical/chart number; when necessary specific charts are retrieved to verify information.

The National Cancer Register records only histopathologically diagnosed cancers. No attempt has been made to search hospital or clinic records for clinically diagnosed malignancy nor to include death certificate data. Limiting registration to histopathologically diagnosed malignancy eliminates local variation in clinical criteria and defines cases by objective histologic criteria. Pathologic criteria were constant between 1974–1978 because only three of Panama’s nine Provinces (Panama, Colon, Chiriqui) had pathologists. Tissue specimens from all other provinces were sent to Panama City and evaluated by the Pathology Department of either Santo Tomas or Seguro Social Hospital. Both have
Table 2. Most commonly diagnosed cancers in Panama, 1974–1978.

<table>
<thead>
<tr>
<th>Site</th>
<th>Rate*</th>
<th>Site</th>
<th>Rate*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male</strong></td>
<td></td>
<td><strong>Female</strong></td>
<td></td>
</tr>
<tr>
<td>Skin</td>
<td>16.9</td>
<td>Uterine*</td>
<td>37.8</td>
</tr>
<tr>
<td>Prostate</td>
<td>14.4</td>
<td>cervix</td>
<td>14.7</td>
</tr>
<tr>
<td>Stomach</td>
<td>10.4</td>
<td>Skin</td>
<td>14.4</td>
</tr>
<tr>
<td>Trachea,Bronchus</td>
<td></td>
<td>Breast</td>
<td>14.4</td>
</tr>
<tr>
<td>Lung</td>
<td>5.0</td>
<td>Stomach</td>
<td>6.1</td>
</tr>
<tr>
<td>Rectum</td>
<td>3.2</td>
<td>Corpus uteri</td>
<td>4.1</td>
</tr>
<tr>
<td>Mouth</td>
<td>3.2</td>
<td>Ovary</td>
<td>3.1</td>
</tr>
<tr>
<td>Larynx</td>
<td>2.7</td>
<td>Mouth</td>
<td>3.7</td>
</tr>
<tr>
<td>Connective tissue</td>
<td>2.3</td>
<td>Rectum</td>
<td>3.1</td>
</tr>
<tr>
<td>Bladder</td>
<td>2.4</td>
<td>Colon</td>
<td>2.4</td>
</tr>
<tr>
<td>Liver</td>
<td>2.1</td>
<td>Other fem. genital tissue</td>
<td>2.4</td>
</tr>
<tr>
<td>Penis</td>
<td>1.9</td>
<td>Connective tissue</td>
<td>1.8</td>
</tr>
</tbody>
</table>

*Incidence per 100,000 population adjusted to standard world population.
*Includes only invasive cervical cancer.

active Pathology Resident training programs and maintain frequent interchange with pathologists from major U.S., South American, and European Medical Schools.

Although the National Cancer Register underestimates true cancer incidence, it has high specificity. Table 2 summarizes the age standardized rates of the most common registered cancers between 1974–1978. Cancer of the uterine cervix was overwhelmingly the most frequent, accounting for 33% of all female cancers. This age-adjusted cervical cancer incidence was among the highest reported in the world.

II. CERVICAL CANCER IN PANAMA

II. A. Epidemiology

In order to investigate this high cervical cancer incidence, Standardized Cervical Cancer Register was established. Registry personnel visited every hospital and regional health center and enumerated all patients diagnosed as having, or certified as dying with, cervical cancer since 1974. The Standardized Register includes all data recommended by the IARC (World Health Organization 1976). It abstracts each patient's entire medical record and frequently includes data from several clinic and hospital charts. All data is maintained on computer files using the Conversational Statistical System for Medical Records (Kronmal et al. 1970).

The Standardized Cervical Cancer Register includes all patients seen between 1974–1978 at Panama City's three Medical Center teaching hospitals (The National Oncology Institute, Santo Tomas Hospital, and Social Security Medical Center). There have been 1,013 cervical cancers registered; 685 invasive and 328 intraepithelial. There were 708 cases detected by the National Cancer Register, and we discovered 305 previously unknown cases. These registered cases represent approximately 60% of all cervical cancers known to occur between 1974–1978. There were only three hospitals in Panama where invasive cervical cancer could be properly evaluated and treated; residents from anywhere in Panama had unrestricted access to their facilities; and physicians from every province were well-instructed in the importance of rapidly referring cancer patients. Thus, these registered cases comprised a representative country-wide sample of invasive cervical cancer.

This sample revealed an invasive cervical cancer incidence of 28.2 per 100,000 women older than 15 years of age (the population at risk). Age-adjusted to the standard world population (Doll 1976) comprises 23.9 cases per 100,000. Six of seven provinces (including the capital) had a uniform age-adjusted invasive cervical cancer incidence of 20.7, while women from Herrera Province, with an age-adjusted rate of 66.3, had a 3.2 fold greater risk.

In addition to presenting a higher invasive cervical cancer incidence, 39/90 cases (43%) registered from Herrera involved women younger than 40 years. The age specific Herrera invasive cervical cancer incidence was significantly different from that seen in the remainder of Panama or other countries (Henderson 1977; Waterhouse et al. 1976; Persaud 1977). This geographic clustering of unusually young cases was reported based on previous data from the National Cancer Register (Reeves et al. 1979; Valdés et al. 1979).

Confounding factors did not account for this clustering. Errors in denominator enumeration would cause an excessive rate. However, Panama
maintained an extremely accurate census and the rural population was not affected by large-scale immigration. Biased case ascertainment did not occur; most Herrera cervical cancers (93%) were confirmed by biopsy (evaluated at the capital). Lastly, Herrera resembled other rural provinces with respect to physician: population ratio, availability of primary health care facilities and patient utilization of such facilities.

Other factors were similar among all provinces. Essentially all women were sexually active with an average of 2.0 life-time sex partners and multiple pregnancies. Most of them were from lower socioeconomic strata. Overall, 661 of 685 (96%) invasive cervical cancers were confirmed by biopsy; 629/661 (95%) were classified as epidermoid carcinoma, the remainder were adenocarcinoma. The ratio was similar in all provinces.

II. B. Clinical parameters

The National Oncology Institute is the only place in Panama with the capability to administer radiation therapy. Therefore virtually all invasive cervical cancer patients were referred, classified and treated there (592 of 685, 86%). Most women presented with advanced disease. However, between 1974–1978, in situ and lower staged cancers showed a relative increase in frequency (Figure 1). This may reflect an increased awareness of cervical cancer and implementation of cancer detection programs in rural areas.

III. CONCLUDING REMARKS

Chronic non-infectious diseases are the most important contributors to mortality in Panama. Cancer has been among the first three causes of death since 1968, and invasive cervical cancer accounted for 33% of all female malignancies. In addition, Panama’s age-adjusted invasive cervical cancer incidence ranked among the highest reported in the world. This is consistent with published data showing that cervical cancer mortality rates have steadily increased in developing countries of Asia, Africa and Latin America (Hill 1975), while concurrently decreasing in industrialized countries (Persaud 1977). The Latin America-Caribbean area supports the highest documented cervical cancer incidence (Caorsi et al. 1976; Hendersen 1977; Madrigal et al. 1976). The three areas reporting cervical cancer incidences comparable to Panama’s (Cali, Colombia; Recife, Brazil; Kingston, Jamaica) have many cultural and ethnic similarities.

In addition to an overall high country-wide cervical cancer incidence, Herrera had an incidence three times greater than the rest of the country. Herrera Province also demonstrated a unique age profile with almost half the cases occurring before

![Figure 1. Percent cervical cancers in each clinical stage who were treated at the National Oncology Institute, 1974-1979.](image-url)
40 years of age. Young women from Herrera were evidently exposed to unique risk factors (Alexander 1973; Kessler and Aurelian 1975). An understanding of these risk factors would not only contribute to the basic epidemiology of cervical cancer but would also allow development of effective local cancer prevention programs.

A cervical cancer situation similar to Panama's also exists in other Central American countries but has not as yet been well documented. It is possible to implement an accurate population-based cancer register in a developing country in spite of limited resources devoted to chronic diseases. Accurate documentation of disease occurrence is necessary to convince and enable individual governments to initiate and support well-planned, effective, cervical cancer detection and treatment programs.

**ACKNOWLEDGEMENT**

This investigation was partly supported by grant number I RO1 CA 25439-01, awarded by the National Cancer Institute, DHEW.

---

**REFERENCES**


